Article Information
History
- August 22, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ariel Israel, MD, PhD1,*,
- Yotam Shenhar, MD1,
- Ilan Green, MD1,2,
- Eugene Merzon, MD1,2,
- Avivit Golan-Cohen, MD1,2,
- Alejandro A Schäffer, PhD3,
- Eytan Ruppin, MD, PhD3,
- Shlomo Vinker, MD, MHA1,2 and
- Eli Magen, MD1,4
- 1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
- 2Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
- 3Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD USA
- 4Medicine C Department, Clinical Immunology and Allergy Division, Barzilai University Medical Center, Ben Gurion University of the Negev, Israel
- ↵*Correspondence to:
Ariel Israel, MD, PhD, Leumit Research Institute, Leumit Health Services, 23 Sprinzak St., Tel-Aviv, Israel, Telephone: 03-6970485, Email: dr.ariel.israel{at}gmail.com
Posted August 22, 2021.
Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection
